Cargando…

Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry

Background: Our aim is to report the results of the ‘liver indication’ subset of patients in the CytoSorb International Registry. Methods: Structured data were recorded. Treatment characteristics and changes from T1 (start of hemoadsorption) to T2 (termination) were evaluated with a special focus on...

Descripción completa

Detalles Bibliográficos
Autores principales: Ocskay, Klementina, Tomescu, Dana, Faltlhauser, Andreas, Jacob, David, Friesecke, Sigrun, Malbrain, Manu, Kogelmann, Klaus, Bogdanski, Ralph, Bach, Friedhelm, Fritz, Harald, Hartjes, Andreas, Kortgen, Andreas, Soukup, Jens, Utzolino, Stefan, van Tellingen, Martijn, Träger, Karl, Schumacher, Ulrike, Brunkhorst, Frank M., Molnar, Zsolt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584981/
https://www.ncbi.nlm.nih.gov/pubmed/34768702
http://dx.doi.org/10.3390/jcm10215182
_version_ 1784597579856609280
author Ocskay, Klementina
Tomescu, Dana
Faltlhauser, Andreas
Jacob, David
Friesecke, Sigrun
Malbrain, Manu
Kogelmann, Klaus
Bogdanski, Ralph
Bach, Friedhelm
Fritz, Harald
Hartjes, Andreas
Kortgen, Andreas
Soukup, Jens
Utzolino, Stefan
van Tellingen, Martijn
Träger, Karl
Schumacher, Ulrike
Brunkhorst, Frank M.
Molnar, Zsolt
author_facet Ocskay, Klementina
Tomescu, Dana
Faltlhauser, Andreas
Jacob, David
Friesecke, Sigrun
Malbrain, Manu
Kogelmann, Klaus
Bogdanski, Ralph
Bach, Friedhelm
Fritz, Harald
Hartjes, Andreas
Kortgen, Andreas
Soukup, Jens
Utzolino, Stefan
van Tellingen, Martijn
Träger, Karl
Schumacher, Ulrike
Brunkhorst, Frank M.
Molnar, Zsolt
author_sort Ocskay, Klementina
collection PubMed
description Background: Our aim is to report the results of the ‘liver indication’ subset of patients in the CytoSorb International Registry. Methods: Structured data were recorded. Treatment characteristics and changes from T1 (start of hemoadsorption) to T2 (termination) were evaluated with a special focus on bilirubin, C-reactive protein, procalcitonin, interleukin-6, platelet levels, SOFA scores, mortality, and subjective assessment by the attending physicians. Results: Until January 2021, from the total 1434 patients, 109 (age: 49.2 ± 17.1 years, 57.8% males) received treatment for hyperbilirubinemia. APACHE II-predicted mortality was 49.6 ± 26.8%. In the study, 91% of patients were alive at the termination of hemoadsorption and improvement was observed by the physicians in 75 cases. Overall, 65 (59.6%) patients died in the hospital, and 60 (55.0%) died in the ICU. Patients received a median of two treatments for a median of 43 h (interquartile range: 24–72 h) in total. Serum bilirubin levels reduced significantly to −4.6 (95% CI: −6.329 to −2.8) mg/dL. Thrombocytopenia was reported in four patients as an adverse event. Conclusions: We report the largest case series on hemoadsorption for ‘liver indication’ from the CytoSorb International Registry. The finding of significant bilirubin removal observed in our study could have substantial impact in designing and executing further studies on the effects of hemoadsorption in liver dysfunction, which are certainly warranted.
format Online
Article
Text
id pubmed-8584981
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85849812021-11-12 Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry Ocskay, Klementina Tomescu, Dana Faltlhauser, Andreas Jacob, David Friesecke, Sigrun Malbrain, Manu Kogelmann, Klaus Bogdanski, Ralph Bach, Friedhelm Fritz, Harald Hartjes, Andreas Kortgen, Andreas Soukup, Jens Utzolino, Stefan van Tellingen, Martijn Träger, Karl Schumacher, Ulrike Brunkhorst, Frank M. Molnar, Zsolt J Clin Med Article Background: Our aim is to report the results of the ‘liver indication’ subset of patients in the CytoSorb International Registry. Methods: Structured data were recorded. Treatment characteristics and changes from T1 (start of hemoadsorption) to T2 (termination) were evaluated with a special focus on bilirubin, C-reactive protein, procalcitonin, interleukin-6, platelet levels, SOFA scores, mortality, and subjective assessment by the attending physicians. Results: Until January 2021, from the total 1434 patients, 109 (age: 49.2 ± 17.1 years, 57.8% males) received treatment for hyperbilirubinemia. APACHE II-predicted mortality was 49.6 ± 26.8%. In the study, 91% of patients were alive at the termination of hemoadsorption and improvement was observed by the physicians in 75 cases. Overall, 65 (59.6%) patients died in the hospital, and 60 (55.0%) died in the ICU. Patients received a median of two treatments for a median of 43 h (interquartile range: 24–72 h) in total. Serum bilirubin levels reduced significantly to −4.6 (95% CI: −6.329 to −2.8) mg/dL. Thrombocytopenia was reported in four patients as an adverse event. Conclusions: We report the largest case series on hemoadsorption for ‘liver indication’ from the CytoSorb International Registry. The finding of significant bilirubin removal observed in our study could have substantial impact in designing and executing further studies on the effects of hemoadsorption in liver dysfunction, which are certainly warranted. MDPI 2021-11-05 /pmc/articles/PMC8584981/ /pubmed/34768702 http://dx.doi.org/10.3390/jcm10215182 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ocskay, Klementina
Tomescu, Dana
Faltlhauser, Andreas
Jacob, David
Friesecke, Sigrun
Malbrain, Manu
Kogelmann, Klaus
Bogdanski, Ralph
Bach, Friedhelm
Fritz, Harald
Hartjes, Andreas
Kortgen, Andreas
Soukup, Jens
Utzolino, Stefan
van Tellingen, Martijn
Träger, Karl
Schumacher, Ulrike
Brunkhorst, Frank M.
Molnar, Zsolt
Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry
title Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry
title_full Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry
title_fullStr Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry
title_full_unstemmed Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry
title_short Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry
title_sort hemoadsorption in ‘liver indication’—analysis of 109 patients’ data from the cytosorb international registry
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584981/
https://www.ncbi.nlm.nih.gov/pubmed/34768702
http://dx.doi.org/10.3390/jcm10215182
work_keys_str_mv AT ocskayklementina hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT tomescudana hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT faltlhauserandreas hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT jacobdavid hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT frieseckesigrun hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT malbrainmanu hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT kogelmannklaus hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT bogdanskiralph hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT bachfriedhelm hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT fritzharald hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT hartjesandreas hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT kortgenandreas hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT soukupjens hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT utzolinostefan hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT vantellingenmartijn hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT tragerkarl hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT schumacherulrike hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT brunkhorstfrankm hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry
AT molnarzsolt hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry